Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Prasugrel to Be Reviewed in US in February
January 12, 2009
- MEDICAL DEVICE NEWS IN BRIEF
January 12, 2009
- Omalizumab, Maraviroc, Nalfurafine Recommended for Approval
January 12, 2009
- Korosho to Restrict Online Sales of Drugs to Class 3 Products
January 12, 2009
- Korosho's General Account Budget for FY2009 Increased to ¥25,156.8 Bil.
January 12, 2009
- Medwatcher Japan Asks Korosho to Conduct Survey on Online Sales of Drugs
January 12, 2009
- FY2009 Budget Proposal Includes ¥24,592 Bil. for Social Security
January 12, 2009
- Consumer, Patient Groups Present Questions to Rakuten
January 12, 2009
- METI to Earmark ¥4.3 Bil. to Develop Regenerative Medicine Technology
January 12, 2009
- Ain to Jointly Open New Store in Sapporo with Seven & i
January 12, 2009
- REGULATORY NEWS IN BRIEF
January 12, 2009
- Take Risks to Develop Breakthrough Drugs: FPMAJ President Dr Takenaka
January 12, 2009
- Takeda Begins PIII Trial of ATL-962 for Obesity Licensed from Alizyme
January 12, 2009
- Seminar
January 12, 2009
- Daiichi Sankyo to Cooperate with Kitasato Institute to Develop Vaccines
January 12, 2009
- Aricept Moves Up to 3rd Place in Domestic Drugs Sales Ranking
January 12, 2009
- PSJ Symposium Calls on Researchers to Venture into New Fields
January 12, 2009
- Daiichi Sankyo to Report Valuation Loss of ¥354 Bil.
January 12, 2009
- R&D NEWS IN BRIEF
January 12, 2009
- Indirect Divisions to Support MRs at Novo Nordisk
January 12, 2009
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…